Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Centrosomal protein 89 (CEP89) is a coiled-coil domain-containing protein predominantly localized to the centrosome and mitochondria. It is essential for the formation of non-motile cilia (ciliogenesis) and plays a critical role in mitochondrial metabolism by regulating cytochrome c oxidase (Complex IV) activity, which affects cellular energy production and mitochondrial integrity. Pathogenic mutations in CEP89 cause various multisystem disorders, including mitochondrial complex IV deficiency, which can manifest as myopathy, hepatomegaly, cardiomyopathy, developmental delay, and intellectual disability. CEP89 is overexpressed in ovarian cancer, where it acts as an independent prognostic marker for poor overall survival, suggesting a possible oncogenic role and making it a candidate for targeted therapeutic development. No drugs directly targeting CEP89 are currently known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Centrosomal protein 89 (CEP89).